Latest news and press releases about Oculis Holding AG (OCS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema.
Price
| Price | $9.91 |
| Market Cap | $567M |
| Exchange | NASDAQ |
| Country | CH |
Valuation Ratios
| Price / Book | 2.24 |
| EV / EBITDA | -6.79 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -42.92% |
| Return on Invested Capital | -38.94% |
| Return on Assets | -31.82% |
| Gross Margin | 35.21% |
| Operating Margin | -35874.24% |
| Net Margin | -32780.20% |
Related companies: ANAB · BBOT · KOD · MNMD · NKTR · NRIX · PHAT
Explore sector: Healthcare · Biotechnology
More sections of OCS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks